Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaTH: PTH and Alendronate in Osteoporosis
NCT00005005Phase 2Completed
- Start
- Oct 1999
- Primary completion
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of parathyroid hormone 1-84 in osteoporosis (4 arms). Primary endpoints: Changes in bone mineral density at 2 years and Changes in biochemical markers at 2 years. Started Oct 1999; status: completed.
02
Drugs
parathyroid hormone 1-84
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00005005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005005.